The FDA expanded Gilead Sciences’ Trodelvy to treat front-line triple-negative breast cancer (TNBC) regardless of PD-L1 status, giving the TROP2 antibody-drug conjugate a broader positioning in the growing first-line ADC market. The updated label allows Trodelvy either as monotherapy for patients ineligible for PD-1/L1 inhibitors or in combination with Merck’s Keytruda for PD-L1-positive tumors (combined positive score ≥10). The approval is supported by two Phase 3 trials. In Ascent-03, Trodelvy reduced the risk of progression or death by 38% versus chemotherapy in PD-(L)1 inhibitor-ineligible patients. In Ascent-04 (Keynote-D19), Trodelvy plus Keytruda improved progression-free survival by 35% versus Keytruda plus chemotherapy in PD-L1-positive disease. Regulatory action lands less than a month after a front-line TNBC approval for Daiichi Sankyo and AstraZeneca’s Datroway (trop2 ADC), setting up head-to-head commercial execution across overlapping biomarker segments. Gilead also highlighted clinical familiarity, citing Trodelvy’s use by more than 75,000 patients globally over six years. For the broader competitive landscape, analysts are watching whether subsequent trials can secure overall survival advantages and further narrow differences in patient selection across the PD-L1-positive and PD-L1-negative settings.